Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

Bone Marrow Transplantation

Volumn 30, Issue 10, 2002, Pages 673-679

  Singhal, S ^a,b   Powles, R ^a   Sirohi, B ^a   Treleaven, J ^a   Kulkarni, S ^a   Mehta, J ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Autotransplantation; Chemosensitivity; High dose melphalan; Multiple myeloma; Primary refractory disease

Indexed keywords

ALPHA2B INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; STEM CELL MOBILIZATION; TREATMENT OUTCOME; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENT DISEASE; REMISSION; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0036861312     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703717     Document Type: Article

References (28)

1. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822-824.
2. Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298-1301.
3. Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298-1301.
4. Powles R, Raje N, Milan S et al. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997; 20: 435-443.
5. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome. New Engl J Med 1996; 335: 91-97.
6. Mehta J, Powles RL. Autologous blood and marrow transplantation. In: Whittaker JA, Holmes JA (eds). Leukaemia and Associated Diseases. Blackwell Science: Oxford, 1998, pp 455-481.
7. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
8. Dimopoulos MA, Hester J, Huh Y et al. Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol 1994; 87: 730-734.
9. Alexanian R, Dimopoulos MA, Hester J et al. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278-4282.
10. Medicare Coverage Policy, Decisions. Autologous stem cell transplantation (AuSCT) for multiple myeloma (#CAG-00011B).
11. Powles R, Milan S, Horton C et al. The Royal Marsden Hospital leukemia-myeloma database: an 'operations research' resource for assessing clinical outcomes and planning new drug trials. Blood 2001; 98 (Suppl. 1): Abstr. 1788.
12. Gore ME, Selby PJ, Viner C et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989; 2: 879-882.
13. Powles R, Raje N, Horton C et al. Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. Leuk Lymphoma 1996; 21: 421-427.
14. Cunningham D, Powles R, Malpas J et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102: 495-502.
15. Vesole DH, Crowley JJ, Catchatourian R et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol 1999; 17: 2173-2179.
16. Rajkumar SV, Fonseca R, Lacy MQ et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 1999; 23: 1267-1272.
17. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. New Engl J Med 1999; 341: 1565-1571.
18. Singhal S, Mehta J. Thalidomide in cancer - potential uses and limitations. BioDrugs 2001; 15: 163-172.
19. Richardson PG, Berenson J, Irwin D et al. Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Blood 2001; 98 (Suppl. 1): Abstr. 3223.
20. Vacca A, Singhal S, Ribatti D, Dammacco F. Angiogenesis in plasma cell disorders. In: Mehta J, Singhal S (eds). Myeloma. Martin Dunitz: London, 2002, pp 119-135.
21. Vesole DH, Barlogie B, Jagannath S et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950-956.
22. Björkstrand B, Goldstone AH, Ljungman P et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. Leuk Lymphoma 1994; 15: 265-272.
23. Desikan KR, Tricot G, Dhodapkar M et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant 2000; 25: 483-487.
24. Sirohi B, Powles R, Mehta J et al. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. Br J Haematol 1999; 107: 656-666.
25. Sirohi B, Powles R, Sumpter K et al. A comparison of kinetics of paraprotein clearance: rapid decline of paraprotein after high-dose melphalan (HDM) versus infusional chemotherapy (IC) in previously untreated patients with IgG multiple myeloma. Bone Marrow Transplant 2000; 25 (Suppl. 1): S218.
26. Powles R, Sirohi B, Kulkarni S et al. Can high-dose melphalan with autotransplantation be used as primary therapy for multiple myeloma as the first step towards an 'operational cure'? Bone Marrow Transplant (submitted).
27. Powles R, Sirohi B, Kulkarni S et al. Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients. Bone Marrow Transplant 2000; 25: 949-956.
28. Powles R, Sirohi B, Treleaven J et al. Continued first complete remission in multiple myeloma for over 10 years: a series of 'operationally cured' patients. Blood 2000; 96 (Suppl. 1): 515a.